华蟾素联合化疗治疗非小细胞肺癌疗效的Meta分析

Meta-analysis of combining bufonin injection with chemotherapy in treatment of patients with non-small cell lung cancer

目的评价华蟾素注射液联合化疗方案治疗非小细胞肺癌（NSCLC）的疗效。方法在中国生物医学文献数据库、中国全文期刊数据库、维普期刊数据库、万方数据库中搜索2000-2011年有关华蟾素注射液联合化疗方案（华蟾素联合化疗组）与单纯化疗方案（单纯化疗组）治疗NSCLC的临床对照试验，对符合纳入标准的文献用RevMan5．0软件进行Meta分析。结果经过筛选，有13篇文献符合入选标准，患者共827例；华蟾素联合化疗组421例，单纯化疗组406例。华蟾素联合化疗组总有效率[比值比（OR）合并=1．68，95％可信区间=1．25～2．25]和疾病控制率（OR合并=2．11，95％可信区间=1．41—3．15）均明显优于单纯化疗组，差异均有统计学意义（P〈0．01），同时没有明显增加药物不良反应。结论在治疗NSCLC疗效方面．华蟾素联合化疗方案优于单用化疗。

Objective To evaluate the efficacy of combining bufonin injection with chemotherapy for nonsmall cell lung cancer（NSCLC） compared with chemotherapy alone. Methods The randomized clinical trials observed the efficacy of combining bufonin injection with chemotherapy and chemotherapy alone from 2000 to 2011 using Chinese Biomedical Literature Database, the Chinese full-text periodical database, VIP journals database, Wanfang database. A meta-analysis was employed to evaluate the results of these therapies by RevMan 5.0. Results Thirteen randomized clinical trials including 827 cases were analyzed. Compared with control group, the total odds ratio of efficiency rate of combining bufonin injection with chemotherapy was OR = 1.68 （95% Cl = 1.25-2.25 ） and the disease control rate was OR = 2.11 （95 % CI = 1.41-3.15 ） ; there were significant difference between two groups （P 〈 0.01 ）. And there was no significant increasing in adverse drug reactions. Combining bufonin injection with chemotherapy could exert better effect. Conclusion Combining bufonin injection with chemotherapy is superior to chemotherapy alone in treatment of NSCLC in total efficiency rate and disease control rate.